Years of NIH-supported studies contributed to the U.S. Food and Drug Administration approval of a new drug for acute intermittent porphyria—a rare, debilitating condition. The NCATS-supported Porphyrias Consortium played a pivotal role in its development.
2020-12-03 NCATS /news-events/news/rdcrn-porphyrias-consortium